Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Few studies have focused on comparing the effect of cognitive frailty (CF) with either cognitive impairment or frailty alone on fall risk. Further, studies investigating the effect of reversible cognitive frailty (RCF) or potentially reversible cognitive frailty (PRCF) on fall risk are scarce. This study aimed to investigate the influence of RCF and PRCF on falls in community-dwelling older adults of China and determine whether CF conferred a higher risk than cognitive impairment or frailty alone.
Methods: This study used data from five waves of the China Health and Retirement Longitudinal Study (CHARLS) conducted from 2011 to 2020. A total of 3,200 participants were divided into six groups: Healthy, cognitive impairment [subjective cognitive decline (SCD) and mild cognitive impairment (MCI)], Frailty, and CF (RCF and PRCF), according to their baseline cognitive and frailty status. A generalized estimating equation was applied to measure the association of cognitive status, frailty, and CF with risk of falls. Multivariate logistic regression models were employed to analyze potential multiplicative and additive interactions of baseline cognitive impairment and frailty on fall risk.
Results: Of the 3,200 participants, 17.7% and 8.3% experienced falls and fall-induced injuries, respectively, in wave 2013. After adjusting for all covariates, the participants in the PRCF group [odds ratio (OR) = 1.442, 95% confidence interval (CI): 1.179-1.922] had a higher risk of falling than those in the RCF group (OR = 1.302, 95% CI: 1.053-1.593), while cognitive impairment alone or frailty alone were not associated with increased risk. The interaction analyses revealed a lack of multiplicative (OR = 0.952, 95% CI: 0.618-1.468) or additive [relative excess risk (RERI) =-0.043, 95% CI: -0.495-0.409; attributable proportion (AP) =-0.035, 95% CI: -0.400-0.329; synergy index (S) = 0.840, 95% CI: 0.172-4.095] interactions of cognitive impairment and frailty for falls.
Conclusions: We found that the risk of falls increased in RCF and PRCF compared to either cognitive impairment or frailty alone, with PRCF being associated with a higher risk than RCF.
Clinical Trial Number: Not applicable.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971774 | PMC |
| http://dx.doi.org/10.1186/s12877-025-05872-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sarcopenia: current state of knowledge and its implications in orthopaedics and traumatology for enhanced clinical strategies and patient outcomes.
Musculoskelet Surg
September 2025
1st Orthopedic Department, IRCCS - Istituto Ortopedico Rizzoli, Bologna, Italy.
Introduction: Sarcopenia is a pathologic condition frequent in aged population, leading to functional and cognitive impairment. Given the ageing of the population worldwide, the topic has generated interest in the last decades and is expected to be more relevant in the near future. This paper aims to present the mechanism of sarcopenia, the current state of knowledge regarding diagnosis and treatment and the role of sarcopenia in orthopaedic and traumatological settings.
View Article and Find Full Text PDFEnhancing healthspan with Ashwagandha (Withania somnifera): a comprehensive review of its multifaceted geroprotective benefits.
Biogerontology
September 2025
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
Ashwagandha (Withania somnifera), a revered herb in Ayurvedic medicine, has gained significant scientific recognition for its potential to promote healthy aging. Traditionally used as a Rasayana or rejuvenator, this potent adaptogen helps the body manage stress and enhance vitality. This review synthesises extensive evidence for its multifaceted anti-aging capabilities, which target key hallmarks of the aging process.
View Article and Find Full Text PDFDopamine System Dysfunction in Alzheimer's Disease.
Psychogeriatrics
September 2025
Clinical Neurosciences and Mental Health Department, Faculty of Medicine of Porto University, Porto, Portugal.
The dopaminergic system may be at the base of some neurobehavioral symptoms, as apathy and depression, and extrapyramidal symptoms, often seen in Alzheimer's disease patients. It can also have an impact on cognitive decline, as extrapyramidal symptoms, classically linked with dopamine dysfunction, are associated with increased risk of cognitive impairment and Alzheimer's disease progression. We review the knowledge of the dopaminergic system, emphasizing changes in Alzheimer's disease.
View Article and Find Full Text PDFInterventions delivered in healthcare settings to promote vaping cessation in children and young people (under the age of 18 years): a scoping review protocol.
BMJ Open
September 2025
Faculty of Health and Medicine, Lancaster University Medical School, Lancaster, UK.
Introduction: Vaping among children and young people (CYP) has increased globally over the past decade, with rates stabilising in the UK in recent years. Factors such as curiosity, social influence, stress management and attractive flavours contribute to its popularity. Although the long-term health impacts are uncertain, vaping poses risks including nicotine dependence, cardiovascular and respiratory issues, and cognitive impairment, though evidence on long-term effects is still emerging.
View Article and Find Full Text PDFCognitive dysfunction in systemic lupus erythematosus: Insights from a two-year longitudinal study in a Brazilian cohort.
Reumatol Clin (Engl Ed)
September 2025
Mackenzie Evangelical School of Medicine, Curitiba, Brazil; Internal Medicine Post Graduate, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil; Department of Medicine, Positivo University, Curitiba, Brazil. Electronic address:
Objectives: The objective of this study was to examine cognitive dysfunction in a Brazilian sample of SLE patients for two years.
Methods: A sample of 50 individuals with SLE was assessed at baseline for epidemiological and treatment data, disease activity by SLEDAI 2K (SLE disease activity 2000), cumulative damage by SLICC/ACR DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), depression by CES-D (Center for Epidemiological Studies-Depression) and cognitive function through MoCA (Montreal Cognitive Assessment). The same assessment was repeated after two years.